Case ReportsSuccessful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemiaOka, Satokoa; Ono, Kazuob; Nohgawa, MasaharuaAuthor Information aDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama bDivision of Pathology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan Received 24 September 2019 Revised form accepted 14 December 2019 Correspondence to Satoko Oka, MD, Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, zip code 640 8558, Japan, Tel: +81 734 22 4171; fax: +81 734 21 8132; e-mail: [email protected] Anti-Cancer Drugs: June 2020 - Volume 31 - Issue 5 - p 536-539 doi: 10.1097/CAD.0000000000000895 Buy Metrics Abstract Although treatments for adult T-cell leukemia/lymphoma in the past two decades have advanced, the current standard treatment for aggressive adult T-cell leukemia/lymphoma, particularly in patients who are not eligible for stem cell transplantation, remains inadequate; therefore, treatments to prolong the duration of remission and provide relevant benefits in terms of survival and quality of life are needed. Adult T-cell leukemia/lymphoma tumor cells express CD30 in some cases and the increased expression of CD30 is considered to be one of the causes of constitutive NF-κB activation in adult T-cell leukemia/lymphoma cells. Brentuximab vedotin represents a major breakthrough in the treatment of CD30-positive lymphomas. Elderly patients treated with chemotherapy generally have higher rates of grade 3 or 4 adverse events; however a retrospective analysis demonstrated the safety and efficacy of brentuximab vedotin in adults ≥60 years with relapsed and refractory CD30-positive lymphomas. We herein report the clinical effects of brentuximab vedotin and the significance of CD30 expression in an elderly refractory/relapse adult T-cell leukemia/lymphoma patient. CD30 expression is associated with disease progression in adult T-cell leukemia/lymphoma patients and brentuximab vedotin may be a new and promising treatment option for these patients. Further investigations on the use of brentuximab vedotin for adult T-cell leukemia/lymphoma are needed. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.